CXCR4 and prostate carcinoma: New targets for prostate cancer are currently being studied, such as neurotensin receptor-1 (NTS1) [10], somatostatin receptor-2 (SST2) [11] or chemokine receptor-4 (CXCR4) [12]—suggested to be expressed in prostate cancer in a few small pilot studies.